The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMXC.L Regulatory News (MXC)

  • There is currently no data for MXC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

21 Jul 2023 10:56

RNS Number : 8235G
MGC Pharmaceuticals Limited
21 July 2023
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

AU000000MXC6

Issuer Name

MGC Pharmaceuticals Limited

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Miton UK MicroCap Trust plc

City of registered office (if applicable)

London

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Name

City of registered office

Country of registered office

BNY (OCS) Nominees Limited

London

England

5. Date on which the threshold was crossed or reached

14-Jul-2023

6. Date on which Issuer notified

18-Jul-2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

4.526895

0.000000

4.526895

176203028

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

AU000000MXC6

176203028

4.526895

Sub Total 8.A

176203028

4.526895%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

18/07/2023

13. Place Of Completion

Exeter, UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUAVKROSUBURR
Date   Source Headline
2nd Sep 20219:05 amRNSSecond Price Monitoring Extn
2nd Sep 20219:00 amRNSPrice Monitoring Extension
2nd Sep 20217:00 amRNSCimetrA import approval granted in India
1st Sep 20217:00 amRNSPreliminary Financial Report for 30 June 2021
31st Aug 20217:00 amRNSProposed Issue of Securities and Appendix 3B
27th Aug 20219:00 amRNSHolder Update - MXCOE Listed Options
26th Aug 20219:05 amRNSSecond Price Monitoring Extn
26th Aug 20219:00 amRNSPrice Monitoring Extension
26th Aug 20217:10 amRNSMGC Pharma executes US$24m agreement with US firm
12th Aug 20211:21 pmRNSResults of General Meeting
6th Aug 20218:47 amRNSGeneral Meeting Information and Webinar
3rd Aug 20217:00 amRNSExpiry of Share Options
26th Jul 20217:00 amRNSQuarterly Results
16th Jul 20217:56 amRNSAmendment to Expiry of Share Options
15th Jul 20217:17 amRNSCannabinoid Patent Application Submitted
13th Jul 202110:52 amRNSExpiry of Share Options
13th Jul 20219:38 amRNSIssue of Shares and Cleansing Statement
12th Jul 20217:00 amRNSPhase III CimetrA™ Clinical Trial Commences
9th Jul 20219:16 amRNSCleansing Notice and Appendix 2A
9th Jul 20217:00 amRNSNotice of GM
15th Jun 20217:00 amRNSCannEpil - Primary Care Reimbursement in Ireland
9th Jun 20217:24 amRNSAppointment of Company Secretary
25th May 20217:00 amRNS2021 Clinical Trials Program Update
17th May 20217:58 amRNSCimetrA Patent Submitted to European IP Office
14th May 20217:59 amRNSAppendix 3G
14th May 20217:50 amRNSAppendix 2A - Issue of Shares
7th May 20217:27 amRNSResearch Update - ArtemiC
6th May 20212:00 pmRNSPrice Monitoring Extension
6th May 20217:31 amRNSASX Trading Halt
4th May 20217:00 amRNSNew ArtemiC Order Received From Swiss PharmaCan AG
28th Apr 20217:00 amRNSApplication to Health Canada for ArtemiC Approval
27th Apr 20217:00 amRNSQuarterly Results
22nd Apr 20217:00 amRNSAcquisition of MediCaNL
21st Apr 202112:36 pmRNSIssue of Equity
9th Apr 20217:00 amRNSInvestor Presentation
8th Apr 202111:00 amRNSCorporate Update
7th Apr 20217:08 amRNSArtemiC Rescue First Delivery and March Revenue
31st Mar 202112:54 pmRNSGM Statement
24th Mar 20219:03 amRNSAppendix 2A - Issue of Shares
22nd Mar 20217:30 amRNSPhase III Clinical Trial of CimetrA Approved
19th Mar 20217:00 amRNSNotice of GM
9th Mar 20218:19 amRNSAppendix 2A - Issue of Shares
9th Mar 20217:00 amRNSDirector/PDMR Shareholding
2nd Mar 20217:00 amRNSIncreased initial supply agreement for ArtemiC
26th Feb 20217:17 amRNSNotice of GM
26th Feb 20217:00 amRNSHalf-year Report
25th Feb 20219:05 amRNSSecond Price Monitoring Extn
25th Feb 20219:00 amRNSPrice Monitoring Extension
19th Feb 20214:41 pmRNSSecond Price Monitoring Extn
19th Feb 20214:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.